NEW YORK: A groundbreaking real-world study presented at the Alzheimer’s Association International Conference (AAIC) 2026 reveals that the anti-amyloid therapy Leqembi (lecanemab) may help over 75% of patients with early Alzheimer’s disease remain clinically stable or even improve after an average of 17 months of treatment.

For decades, the medical community has viewed Alzheimer’s disease as an inevitably progressive neurodegenerative condition. However, this interim analysis from the LEADER (Lecanemab in Early Alzheimer’s Disease) study offers a paradigm shift, suggesting that disease-modifying therapies can meaningfully preserve cognitive function in routine clinical practice.

Unprecedented Clinical Stability

The retrospective analysis encompassed 432 participants who had received at least seven Leqembi infusions. Researchers reported that 75.9% of patients remained at the same broad disease stage, while an additional 6.6% improved by one disease stage (e.g., transitioning from mild dementia to mild cognitive impairment). Consequently, an impressive 82.5% of evaluable participants were either stable or showed improvement.

Notably, this clinical stability was observed consistently across diverse demographics, regardless of sex, race, ethnicity, or APOE ε4 genetic status, a gene variant historically associated with an elevated risk of Alzheimer’s pathology.

Safety and Treatment Persistence

A critical metric for any novel therapeutic is its efficacy coupled with tolerability. The study noted that nearly 87% of participants elected to continue Leqembi treatment, indicating high treatment persistence in everyday medical settings.

Regarding safety, the profile remained consistent with previous randomized controlled trials. Amyloid-related imaging abnormalities (ARIA), a known potential side effect of anti-amyloid therapies, occurred in 12.3% of participants. However, the vast majority of these cases were reported as mild and asymptomatic, aligning with the drug’s established safety parameters.

Expert Caution and Future Directions

Despite the encouraging outcomes, medical experts urge cautious interpretation. Dr. Dung Trinh, an internist and Chief Medical Officer of the Healthy Brain Clinic, emphasized that the LEADER study is observational and lacks an untreated comparison group. Therefore, it cannot definitively isolate the medication's effect from natural disease variability.

"The results are most useful as evidence about real-world feasibility, persistence, monitoring, and safety," Dr. Trinh noted. "Clinicians should view the LEADER findings as supportive and hypothesis-generating rather than absolute proof of a treatment effect."

As the FDA continues to evaluate supplemental applications for more convenient administration routes, such as subcutaneous injections, real-world evidence will be pivotal in shaping future treatment guidelines. The LEADER study underscores the necessity of coordinated care pathways, ensuring that patients receive comprehensive diagnostic, imaging, and monitoring support throughout their therapeutic journey.